Drug-Induced Acute Kidney Injury: A Study from the French Medical Administrative and the French National Pharmacovigilance Databases Using Capture-Recapture Method.
French medical information system program
French pharmacovigilance database
KDIGO
capture-recapture method
drug-induced acute kidney injury
notification rate
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
06 Jan 2021
06 Jan 2021
Historique:
received:
20
11
2020
revised:
26
12
2020
accepted:
31
12
2020
entrez:
9
1
2021
pubmed:
10
1
2021
medline:
10
1
2021
Statut:
epublish
Résumé
Acute kidney injury (AKI) is a public health concern. Among the pathological situations leading to AKI, drugs are preventable factors but are still under-notified. We aimed to provide an overview of drug-induced AKI (DIAKI) using pharmacovigilance and medical administrative databases Methods: A query of the PMSI database (French Medical Information System Program) of adult inpatient hospital stays between 1 January 2017 and 31 December 2018 was performed using ICD-10 (International Classification of Diseases 10th revision) codes to identify AKI cases which were reviewed by a nephrologist and a pharmacovigilance expert to identify DIAKI cases. In parallel, DIAKIs notified in the French Pharmacovigilance Database (FPVDB) were collected. A capture-recapture method was performed to estimate the total number of DIAKIs. The estimated total number of DIAKIs was 521 (95%CI 480; 563), representing 20.0% of all AKIs. The notification was at a rate of 12.9% (95%CI 10.0; 15.8). According to the KDIGO classification, 50.2% of the DIAKI cases were stage 1 and 49.8% stage 2 and 3. The mortality rate was 11.1% and 9.6% required hemodialysis. This study showed that drugs are involved in a significant proportion of patients developing AKI during a hospital stay and emphasizes the severity of DIAKI cases.
Sections du résumé
BACKGROUND
BACKGROUND
Acute kidney injury (AKI) is a public health concern. Among the pathological situations leading to AKI, drugs are preventable factors but are still under-notified. We aimed to provide an overview of drug-induced AKI (DIAKI) using pharmacovigilance and medical administrative databases Methods: A query of the PMSI database (French Medical Information System Program) of adult inpatient hospital stays between 1 January 2017 and 31 December 2018 was performed using ICD-10 (International Classification of Diseases 10th revision) codes to identify AKI cases which were reviewed by a nephrologist and a pharmacovigilance expert to identify DIAKI cases. In parallel, DIAKIs notified in the French Pharmacovigilance Database (FPVDB) were collected. A capture-recapture method was performed to estimate the total number of DIAKIs.
RESULTS
RESULTS
The estimated total number of DIAKIs was 521 (95%CI 480; 563), representing 20.0% of all AKIs. The notification was at a rate of 12.9% (95%CI 10.0; 15.8). According to the KDIGO classification, 50.2% of the DIAKI cases were stage 1 and 49.8% stage 2 and 3. The mortality rate was 11.1% and 9.6% required hemodialysis.
CONCLUSION
CONCLUSIONS
This study showed that drugs are involved in a significant proportion of patients developing AKI during a hospital stay and emphasizes the severity of DIAKI cases.
Identifiants
pubmed: 33418844
pii: jcm10020168
doi: 10.3390/jcm10020168
pmc: PMC7824808
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Clin J Am Soc Nephrol. 2018 Dec 7;13(12):1897-1908
pubmed: 29622670
JAMA. 2002 Oct 2;288(13):1586; author reply 1587-8
pubmed: 12350185
Nat Rev Nephrol. 2010 Aug;6(8):461-70
pubmed: 20517290
Epidemiol Rev. 1995;17(2):243-64
pubmed: 8654510
Expert Opin Drug Saf. 2008 Nov;7(6):679-90
pubmed: 18983215
Drug Saf. 2006;29(5):385-96
pubmed: 16689555
Nephrol Dial Transplant. 2004 Jan;19(1):8-11
pubmed: 14671029
Br J Clin Pharmacol. 2020 Jun 2;:
pubmed: 32484575
Eur J Clin Pharmacol. 2014 Dec;70(12):1519-26
pubmed: 25304009
Nephron Physiol. 2008;109(4):p61-72
pubmed: 18802377
Br J Clin Pharmacol. 2017 Jun;83(6):1341-1349
pubmed: 28002877
Drug Saf. 1996 Sep;15(3):200-11
pubmed: 8879974
JAMA. 2005 Aug 17;294(7):813-8
pubmed: 16106006
Kidney Int. 2010 Jun;77(11):956-61
pubmed: 20336051
Kidney Int. 2011 Jan;79(1):33-45
pubmed: 20861826
Crit Care Med. 2008 Apr;36(4 Suppl):S216-23
pubmed: 18382197
J Nephrol. 2020 Dec;33(6):1171-1187
pubmed: 32651850
Rev Epidemiol Sante Publique. 2002 Apr;50(2):219-32
pubmed: 12011737
Kidney Int. 2004 Oct;66(4):1613-21
pubmed: 15458458
Lancet. 2013 Jul 13;382(9887):170-9
pubmed: 23727171
Dtsch Arztebl Int. 2019 May 31;116(22):397-404
pubmed: 31366430
Mater Sociomed. 2015 Apr;27(2):70-4
pubmed: 26005378
J Clin Med. 2020 Jun 27;9(7):
pubmed: 32605085
Am J Kidney Dis. 2002 May;39(5):930-6
pubmed: 11979336
Expert Opin Drug Saf. 2020 Feb;19(2):167-186
pubmed: 31914328
Br J Clin Pharmacol. 2006 Aug;62(2):225-31
pubmed: 16842398
J Am Soc Nephrol. 2005 Nov;16(11):3365-70
pubmed: 16177006
Drug Saf. 2009;32(1):19-31
pubmed: 19132802
Postgrad Med. 2010 Nov;122(6):154-64
pubmed: 21084792
Clin J Am Soc Nephrol. 2013 Sep;8(9):1482-93
pubmed: 23744003
Insights Imaging. 2013 Dec;4(6):811-20
pubmed: 24092564
Proc (Bayl Univ Med Cent). 2016 Oct;29(4):412-413
pubmed: 27695180